Business
AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder
EMP-01 demonstrated a large, clinically meaningful reduction in patient-reported SAD symptoms at Day 43: placebo-adjusted LSMD -11.5 points (p=0.002) on SPIN; placebo-adjusted LSMD -15.6 points (p=0.004) on SAFE - a 38% and 32% reduction, respectivelyPatient-perceived global improvement: 49% PGI-C responders at Day 43 compared to 12% on placeboNo severe or serious adverse events NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-
About this update from Ataibeckley Inc.
[{"type":"image","alt":"AtaiBeckley Inc.","displaySize":"","headline":null,"caption":"AtaiBeckley Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":29,"url":"https://media.zenfs.com/en/globenewswire.com/1c769bfebfd9f7f9a76a66cc21f516f7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/N747G6EBtYISeRw6dK5Nfw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTQx/https://media.zenfs.com/en/globenewswire.com/1c769bfebfd9f7f9a76a66cc21f516f7","width":150,"height":29}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"EMP-01 demonstrated a large, clinically meaningful reduction in patient-reported SAD symptoms at Day 43: placebo-adjusted LSMD -11.5 points (p=0.002) on SPIN; placebo-adjusted LSMD -15.6 points (p=0.004) on SAFE - a 38% and 32% reduction, respectively","length":251,"tagName":"p"}]},{"val":[{"type":"text","content":"Patient-perceived global improvement: 49% PGI-C responders at Day 43 compared to 12% on placebo","length":95,"tagName":"p"}]},{"val":[{"type":"text","content":"No severe or serious adverse events","length":35,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":381,"olType":false},{"type":"text","content":"NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced expanded Phase 2a results for EMP-01 (oral R-MDMA) in adults with Social Anxiety Disorder (SAD) (n=70), demonstrating clinically meaningful and consistent improvements across clinician-rated symptoms, patient-reported experience, and real-world behavioral outcomes. At Day 43, EMP‑01 achieved a 38% reduction vs 15% on placebo (Hedges’ g=0.84) on the patient-reported Social Phobia Inventory (SPIN), a 32% reduction vs 14% on placebo on the Subtle Avoidance Frequency Examination (SAFE), and a previously reported −11.9-point LS mean difference (LSMD) on the Liebowitz Social Anxiety Scale (LSAS) versus placebo (g=0.45), with 49% responder rates on both Clinical Global Impression-Improvement (CGI-I) (previously reported) and Patient Global Impressions of Change (PGI-C). EMP-01 was well tolerated, with no severe or serious adverse events.","length":1129,"tagName":"p"},{"type":"table","headerItems":[],"...